# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0194 |
| Population Package | PP-0194 |
| Title | EMR (Endoscopic Mucosal Resection) |
| Version | 1.0.0 |
| Review Status | PASS |
| Production Status | GOLD |
| Evidence Basis | Project Source Files |
| Decision Status | APPROVED / LOCKED |
| Last Updated | 2026-08-09 |

---

# QA Scope

This QA Report verifies that the PP-0194 Gold package:

1. implements the approved and locked PP-0194 EMR Decision Batch;
2. follows the locked Population Package architecture;
3. preserves the absolute Gold-depth standard;
4. remains source-grounded in the supplied project materials;
5. maintains a non-duplicative boundary with endoscopic-resection strategy, ESD, pathology, staging, and surgery;
6. provides patient-facing clinical education without individualized treatment advice;
7. contains all four required Gold artifacts;
8. maintains Knowledge Graph and evidence-traceability requirements;
9. is ready for integration.

---

# Layer 1 — Content QA

| Criterion | Result | QA Note |
|---|---|---|
| Single educational question | PASS | The package answers what EMR is, when it may be used, how its specimen is assessed, and its limitations. |
| Atomic scope | PASS | EMR is treated as a specific modality rather than the entire endoscopic-resection strategy. |
| Scope respected | PASS | The package remains focused on EMR and does not become a procedural manual or general gastric-cancer treatment package. |
| Complete coverage | PASS | Definition, selection, specimen, pathology, curative assessment, non-curative pathways, comparison with ESD/surgery, outcomes, safety and surveillance are covered. |
| Internal consistency | PASS | CKO, KP, Evidence Package and QA use the same EMR ownership model. |
| Logical organization | PASS | Content follows selection → EMR → specimen → pathology → curative assessment → downstream management. |
| Clinical knowledge blocks complete | PASS | Independent patient-facing blocks cover the full locked scope. |
| Common misconceptions addressed | PASS | Dedicated misconceptions cover selection, cure, margins, ESD, surgery, lymph-node risk and outcomes. |
| Patient-facing key messages present | PASS | Twelve concise key messages are included. |
| Patient questions included | PASS | Pre-EMR and post-pathology question sets are included. |
| Knowledge Graph complete | PASS | Prerequisite, related and downstream relationships are defined. |
| Boundary complete | PASS | Core / Supporting / Explicitly Excluded / Delegated-to PP are defined. |
| Adjacent ownership controlled | PASS | The package explicitly separates ER strategy, EMR, ESD, pathology, staging and surgery. |

---

# Layer 2 — Clinical QA

## Clinical Source Alignment

| Criterion | Result | QA Note |
|---|---|---|
| Source-first rule respected | PASS | Relevant project Source Files were searched before production. |
| NCCN v2.2026 used as primary current guideline | PASS | GAST-A and GAST-B content is used for current ER/EMR criteria and pathology reporting. |
| NCI PDQ incorporated | PASS | Classic EMR population and historical outcome evidence are represented. |
| NCI patient-facing treatment source incorporated | PASS | EMR definition and patient/care-team context are represented. |
| Vietnamese guideline incorporated | PASS | Regional endoscopic-resection indications and curative concepts are represented. |
| ESMO-ASCO context preserved | PASS | Multidisciplinary/early-localized treatment context is used conservatively. |
| No silent external evidence substitution | PASS | No web or external evidence was added to the Evidence Package. |

---

# Clinical Accuracy Review

| Criterion | Result | QA Note |
|---|---|---|
| EMR definition accurate | PASS | EMR is described as an endoscopic mucosal-resection modality. |
| Early gastric cancer role accurate | PASS | EMR is restricted to selected early/superficial disease. |
| Classic favorable-risk population accurately represented | PASS | Tis/T1a, small size, favorable differentiation and no ulceration are described as classic favorable features from NCI/Vietnamese sources. |
| Nodal-risk rationale accurate | PASS | EMR is framed as appropriate only when expected nodal risk is sufficiently low. |
| Depth-of-invasion importance accurate | PASS | Current NCCN framework and pathology requirements are preserved. |
| ≤500 μm threshold accurately qualified | PASS | Presented as part of the current NCCN curative ER framework, not as an isolated patient self-test. |
| LVI appropriately represented | PASS | LVI is included in pathology and curative assessment. |
| Margin requirements accurate | PASS | Lateral and deep margins are explicitly included. |
| Histology appropriately qualified | PASS | Favorable differentiation is described without reproducing detailed pathology taxonomy. |
| Ulceration appropriately qualified | PASS | Ulceration is treated as a selection factor, not an absolute isolated rule. |
| En-bloc concept accurate | PASS | Explained conceptually without unsupported procedural mechanics. |
| Curative status appropriately qualified | PASS | Curative status is presented as multidimensional. |
| Non-curative features accurately represented | PASS | Deep invasion, LVI, poor differentiation, positive margins and nodal disease are included per NCCN. |
| EMR vs ESD accurately represented | PASS | ESD greater en-bloc capability and current NCCN preference are preserved. |
| Expanded ESD indications not misapplied to EMR | PASS | Explicit guardrail included. |
| EMR vs surgery appropriately framed | PASS | Strategic comparison only; no surgical technique. |
| Historical outcomes accurately qualified | PASS | Study-specific outcomes are not presented as individual predictions. |
| Asian evidence context accurately represented | PASS | Source-supported concentration of experience in Japan/Asia is acknowledged. |
| Center expertise appropriately represented | PASS | NCCN/NCI emphasis on experienced centers/endoscopists is included. |
| Surveillance appropriately represented | PASS | Need for follow-up is included without inventing a universal interval. |

---

# Clinical Safety Review

| Item | Result | QA Note |
|---|---|---|
| No individualized EMR eligibility decision | PASS | Package explains selection factors but does not decide eligibility for an individual patient. |
| No instruction to start/stop/change treatment | PASS | Explicitly excluded. |
| No individualized prognosis | PASS | Historical outcomes are clearly contextualized. |
| No individualized pathology interpretation | PASS | Actual pathology interpretation remains with GI pathology/clinical team. |
| No detailed procedural instruction | PASS | Technical EMR mechanics are explicitly excluded. |
| No detailed complication-management instruction | PASS | High-level risk only. |
| No unsafe “small lesion = EMR” shortcut | PASS | Multiple selection factors are repeatedly emphasized. |
| No unsafe “T1a = automatic EMR” shortcut | PASS | T1a is presented as one component of selection. |
| No unsafe “negative margin = cure” claim | PASS | Curative assessment is multidimensional. |
| No unsafe “EMR removes nodal risk” claim | PASS | Nodal-risk rationale explicitly explained. |
| No unsafe “ESD indications = EMR indications” claim | PASS | Dedicated guardrail included. |
| No universal complication rate invented | PASS | Evidence gap explicitly documented. |
| No universal surveillance interval invented | PASS | Exact interval delegated to current clinical guidance and surveillance PP. |
| Appropriate referral to clinical team | PASS | Patient-facing question sets direct discussion with the care team. |

---

# Layer 3 — Educational QA

| Criterion | Result | QA Note |
|---|---|---|
| Plain language | PASS | Medical terms are explained at first use. |
| Patient-friendly wording | PASS | Questions and explanations are written for patients/caregivers. |
| Technical terms controlled | PASS | EMR, ESD, LVI, en-bloc, margins and depth are explained conceptually. |
| Learning objectives satisfied | PASS | Objectives map directly to knowledge blocks. |
| Logical learning progression | PASS | Selection → procedure → specimen → pathology → curative status → next steps. |
| Practical usefulness | PASS | Before-EMR and after-pathology questions included. |
| Common misconceptions addressed | PASS | Dedicated section included. |
| Uncertainty appropriately communicated | PASS | Evidence gaps and context dependence are explicitly stated. |
| Avoids overpromising | PASS | EMR is not described as universally curative or superior. |
| Appropriate distinction between guideline and historical evidence | PASS | Current NCCN framework is distinguished from historical cohort outcomes. |
| Patient autonomy preserved | PASS | Package supports discussion rather than prescribing treatment. |
| No unnecessary jargon | PASS | Detailed procedural language is intentionally excluded. |

---

# Layer 4 — Governance QA

| Criterion | Result | QA Note |
|---|---|---|
| CKO completed | PASS | 01_CKO.md produced. |
| Knowledge Passport completed | PASS | 02_KNOWLEDGE_PASSPORT.md produced. |
| Evidence Package completed | PASS | 03_PRIMARY_EVIDENCE_PACKAGE.md produced. |
| QA Report completed | PASS | This artifact completed. |
| Gold specification followed | PASS | Four-artifact structure and required sections are preserved. |
| Approved Decision Batch respected | PASS | Locked PP-0194 EMR scope is implemented without reopening scope. |
| Gold reference depth preserved | PASS | Package is intentionally full-depth and not compacted. |
| Gold CKO structure preserved | PASS | Metadata, objectives, scope, knowledge blocks, misconceptions, key messages, graph and revision history included. |
| Gold KP structure preserved | PASS | Identity, classification, runtime usage, retrieval, graph, scope, sources, evidence classification, gaps and governance included. |
| Gold EP structure preserved | PASS | Clinical question, scope, primary/supporting sources, hierarchy, matrix, claims, gaps, delegation, future triggers and boundary verification included. |
| Four-layer QA completed | PASS | Content, Clinical, Educational and Governance QA completed. |
| Knowledge Graph complete | PASS | Prerequisite, related and downstream relationships included. |
| Evidence traceability complete | PASS | Major claims are mapped to supplied sources and page locations. |
| Boundary ownership preserved | PASS | Core / Supporting / Explicitly Excluded / Delegated-to PP structure maintained. |
| Semantic versioning compliant | PASS | Version 1.0.0. |
| Artifact naming compliant | PASS | Standard artifact filenames used. |
| ZIP naming compliant | PASS | PP number and full package title included. |
| Repository-ready structure | PASS | Four Markdown artifacts contained in one package directory and ZIP. |

---

# Gold Artifact Completeness Check

| Artifact | Present | Structural QA |
|---|---|---|
| 01_CKO.md | PASS | Identity, objectives, scope, included/excluded, knowledge blocks, misconceptions, key messages, Knowledge Graph and revision history present |
| 02_KNOWLEDGE_PASSPORT.md | PASS | Identity, classification, runtime relevance, retrieval terms, Knowledge Graph, scope, evidence classification, sources, gaps, governance and versioning present |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | PASS | Clinical question, scope, sources, hierarchy, evidence matrix, claims, interpretation, guardrails, gaps, delegation, future triggers and boundary verification present |
| 04_QA_REPORT.md | PASS | Four QA layers, clinical safety, educational boundary, traceability, completeness and final decision present |

---

# Evidence Traceability QA

## Primary Claims

### EMR definition and role

Traceable to:

- NCI Treatment of Stomach Cancer, PDF p.1.
- NCI Gastric Cancer Treatment PDQ, pp.17–19.
- NCCN GAST-A, pp.18–20.

### Selection

Traceable to:

- NCCN GAST-A, pp.18–20.
- NCI PDQ, pp.17–19.
- Vietnamese guideline, pp.13–14.

### Pathology and curative assessment

Traceable to:

- NCCN GAST-A, pp.19–20.
- NCCN GAST-B, p.22.
- Vietnamese guideline, p.14.

### EMR versus ESD

Traceable to:

- NCCN GAST-A, p.20.
- Vietnamese guideline, p.14.

### Historical outcomes

Traceable to:

- NCI PDQ, pp.17–19.
- NCCN discussion, supplied MS-10 discussion page / PDF p.73.

### Expertise and surveillance

Traceable to:

- NCCN GAST-A, pp.18–20.
- NCI PDQ, p.17.

---

# Source-Gap QA

The following topics were deliberately not expanded beyond source support:

- detailed EMR procedural mechanics;
- EMR-specific universal complication rates;
- anesthesia/sedation;
- individualized eligibility;
- individualized pathology interpretation;
- universal surveillance schedule.

Result:

**PASS — gaps are acknowledged rather than silently filled.**

---

# Adjacent Population Package Overlap QA

## Upstream — PP-0192 Endoscopic Resection for Early Gastric Cancer

**Boundary preserved.**

PP-0192 owns the umbrella strategy:

> Can early gastric cancer be treated endoscopically?

PP-0194 owns:

> What is EMR and how is this specific modality selected and assessed?

---

## Adjacent — ESD-specific PP

**Boundary preserved.**

PP-0194 introduces EMR-versus-ESD strategy only.

It does not own:

- detailed ESD technique;
- detailed ESD selection methodology;
- ESD-specific complication management.

---

## Pathology — PP-0178

**Boundary preserved.**

PP-0194 explains why pathology elements matter after EMR.

PP-0178 owns detailed histopathologic characterization.

---

## Staging / EUS

**Boundary preserved.**

PP-0194 explains why pre-treatment staging matters.

Dedicated EUS/staging packages own detailed methodology.

---

## Surgery

**Boundary preserved.**

PP-0194 explains why non-curative/unsuitable EMR may lead to additional treatment.

Surgical PPs own gastrectomy and lymphadenectomy technique and detailed surgical decision pathways.

---

# Registry / Identity QA

The Project Coordinator's explicit locked instruction for this production is:

> **PP-0194 — EMR (Endoscopic Mucosal Resection).**

This explicit execution identity is used throughout all four artifacts.

A source registry snapshot available in the project Source Files contains a conflicting/stale PP-number mapping around the EMR/ESD sequence. Under the locked governance rule that the Project Coordinator's explicit PP request controls execution, this does not change the production identity of the current package.

The clinical ownership of EMR itself is not ambiguous.

Result:

**PASS — execution identity follows the Project Coordinator's locked instruction.**

---

# Absolute Gold Depth QA

| Dimension | Result | QA Note |
|---|---|---|
| Structural depth | PASS | Gold four-artifact structure preserved. |
| Clinical reasoning depth | PASS | Selection, pathology, curative assessment and downstream logic fully developed. |
| Evidence depth | PASS | Multiple primary project sources and a claim-level evidence matrix included. |
| Patient-facing depth | PASS | 40 clinical knowledge blocks plus misconceptions and question sets. |
| Knowledge Graph depth | PASS | Prerequisites, related nodes and downstream nodes defined. |
| Boundary depth | PASS | Ownership separated from umbrella ER, ESD, pathology, staging and surgery. |
| QA depth | PASS | Four-layer QA plus clinical safety, source-gap, overlap and completeness review included. |
| No compaction | PASS | Content was not reduced to a short summary relative to the approved Gold references. |

---

# Final Quality Decision

# PASS

PP-0194 satisfies the locked **FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1**, the approved/locked PP-0194 EMR Decision Batch, and the Gold workflow requirements.

The package maintains the intended architecture:

**PP-0192 — Endoscopic Resection for Early Gastric Cancer**

↓

# **PP-0194 — EMR (Endoscopic Mucosal Resection)**

↓

**ESD-specific endoscopic-resection package**

↓

**Gastrectomy / downstream surgical and treatment packages**

The package does not duplicate substantive ownership of:

- the umbrella endoscopic-resection strategy;
- ESD-specific knowledge;
- detailed pathology;
- detailed staging/EUS;
- surgical technique;
- systemic treatment;
- surveillance/recurrence management.

The package preserves the central safety distinction:

> **Technical removal of a lesion is not the same as proof of curative cancer treatment.**

Curative status depends on the integrated clinical and pathology assessment.

---

# Reviewer Notes

PP-0194 functions as the **modality-specific EMR node** in the early-gastric-cancer endoscopic-treatment knowledge graph.

Its primary value is to translate a technically specialized procedure into a patient-understandable clinical pathway:

**Why EMR?**

↓

**Is the lesion appropriate?**

↓

**What does EMR remove?**

↓

**What does the specimen show?**

↓

**Was the resection curative?**

↓

**What happens next?**

The package deliberately avoids two unsafe shortcuts:

1. **Small/T1a lesion → automatic EMR.**
2. **Lesion removed → automatic cure.**

It also explicitly prevents a third architecture error:

3. **Expanded ESD indications → automatic EMR indications.**

---

# Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**


# Detailed Clinical Claim Verification

## Claim Family A — Definition and Role

| Check | Result | Verification |
|---|---|---|
| EMR expansion is correct | PASS | Endoscopic mucosal resection is used consistently throughout. |
| EMR is described as endoscopic | PASS | No surgical incision-based description is substituted. |
| EMR is described as a treatment modality | PASS | Treatment ownership is explicit. |
| EMR is linked to early gastric cancer | PASS | The package does not broaden EMR to unrelated gastrointestinal malignancies. |
| EMR is not equated with all ER | PASS | ER remains the umbrella concept in the knowledge graph. |
| EMR is not equated with ESD | PASS | Dedicated modality distinction is maintained. |
| EMR is not presented as universally appropriate | PASS | Selection is repeatedly emphasized. |

## Claim Family B — Selection

| Check | Result | Verification |
|---|---|---|
| Tis/T1a context represented | PASS | NCI/NCCN-supported early-stage context included. |
| Size ≤2 cm represented | PASS | Included as a classic/current favorable feature. |
| Histologic differentiation represented | PASS | Included as a selection and curative factor. |
| Ulceration represented | PASS | Included as a selection signal. |
| Depth represented | PASS | Included in pre-treatment and pathology assessment. |
| Nodal-risk rationale represented | PASS | Explicitly linked to absence of lymph-node dissection in EMR. |
| LVI represented | PASS | Included in pathology and curative assessment. |
| Complete resection represented | PASS | Technical and oncologic completeness are distinguished. |
| Margin status represented | PASS | Lateral and deep margins included. |
| Selection not reduced to one criterion | PASS | Multiple-factor framework used. |

## Claim Family C — Pathology

| Check | Result | Verification |
|---|---|---|
| Histologic type included | PASS | Included as a required EMR pathology element. |
| Grade included | PASS | Included without duplicating full pathology methodology. |
| Depth of submucosal invasion included | PASS | Included with current NCCN threshold context. |
| Vascular/lymphatic invasion included | PASS | Included. |
| Mucosal/deep margins included | PASS | Included. |
| GI pathology expertise included | PASS | High-level center/pathology expertise included. |
| Pathology methodology excluded | PASS | No laboratory processing or microscopic taxonomy manual is presented. |
| Pathology interpretation individualized | PASS | Explicitly delegated. |

## Claim Family D — Curative Assessment

| Check | Result | Verification |
|---|---|---|
| Curative status is multidimensional | PASS | Explicitly stated. |
| Negative margins are necessary but not sufficient | PASS | Explicitly stated. |
| No LVI is included | PASS | Current NCCN framework preserved. |
| Superficial invasion is included | PASS | Current NCCN framework preserved. |
| Favorable differentiation is included | PASS | Current NCCN framework preserved. |
| Size is included | PASS | Current NCCN framework preserved. |
| Complete excision is included | PASS | Current NCCN framework preserved. |
| Curative status is not declared for an individual | PASS | Educational framing maintained. |

## Claim Family E — Non-Curative / Incomplete Resection

| Check | Result | Verification |
|---|---|---|
| Positive margins included | PASS | NCCN-supported. |
| Deep submucosal invasion included | PASS | NCCN-supported. |
| LVI included | PASS | NCCN-supported. |
| Poor differentiation included | PASS | NCCN-supported. |
| Nodal metastasis included | PASS | NCCN-supported. |
| Additional treatment interface included | PASS | Strategic only. |
| Surgery described as automatically required in every case | PASS | Not stated; additional management is context-dependent. |
| Systemic treatment algorithm reproduced | PASS | Explicitly excluded. |

## Claim Family F — EMR versus ESD

| Check | Result | Verification |
|---|---|---|
| ESD greater en-bloc capability represented | PASS | NCCN-supported. |
| ESD preference represented | PASS | Current NCCN wording preserved at high level. |
| Greater technical skill/instrumentation represented | PASS | NCCN-supported. |
| Perforation risk context represented | PASS | High-level only. |
| EMR remains relevant | PASS | NCI/Vietnamese guideline-supported. |
| Expanded ESD criteria not transferred to EMR | PASS | Explicit safety boundary. |
| Detailed ESD technique excluded | PASS | Scope preserved. |

## Claim Family G — EMR versus Surgery

| Check | Result | Verification |
|---|---|---|
| Stomach-preserving potential represented | PASS | Core patient-facing value. |
| Lack of regional lymph-node dissection represented | PASS | Central biological limitation. |
| Surgery remains relevant | PASS | Non-curative/unsuitable pathway included. |
| Surgical technique excluded | PASS | No gastrectomy or lymphadenectomy procedural content. |
| EMR not described as universally superior | PASS | Balanced framing. |

## Claim Family H — Outcomes

| Check | Result | Verification |
|---|---|---|
| NCI prospective cohort size represented | PASS | 445 patients / 479 tumors. |
| Complete-resection outcome represented | PASS | 2% local recurrence and reported disease-free survival preserved. |
| Incomplete-resection recurrence represented | PASS | 18 of 127 described. |
| NCCN 124-patient survival data represented | PASS | 5- and 10-year survival figures included. |
| NCCN 215-patient comparative study represented | PASS | Hospital-stay and death/recurrence context included. |
| Outcomes labeled historical/study-specific | PASS | Explicitly qualified. |
| Outcome data converted into individual prognosis | PASS | Explicitly prohibited. |

# Detailed Educational Claim Verification

| Educational Principle | Result | Verification |
|---|---|---|
| One concept per paragraph | PASS | CKO uses short conceptual blocks. |
| Medical terminology explained | PASS | EMR, ESD, LVI, en-bloc and margins are explained. |
| Patient-facing language | PASS | Questions and direct explanations are used. |
| Neutral tone | PASS | No promotional or alarmist wording. |
| Uncertainty preserved | PASS | Context-dependent statements are labeled. |
| No false reassurance | PASS | Cure is not equated with technical removal. |
| No unnecessary technical detail | PASS | Procedural mechanics excluded. |
| Patient autonomy preserved | PASS | Questions support clinician discussion. |
| No treatment instruction | PASS | No individualized treatment changes are instructed. |
| No individualized prognosis | PASS | Historical outcomes are contextualized. |

# Detailed Governance Linkage Verification

## CKO → KP

**PASS.**

The CKO defines the clinical content and ownership of EMR. The Knowledge Passport converts the same scope into retrieval and runtime metadata without changing the clinical meaning.

## CKO → Evidence Package

**PASS.**

The Evidence Package supplies the evidence basis for the CKO's principal clinical claims. The Evidence Package does not introduce a broader clinical scope than the CKO.

## Evidence Package → QA

**PASS.**

The QA Report verifies the major claims, sources, evidence gaps, and scope boundaries documented in the Evidence Package.

## Knowledge Graph → Boundary

**PASS.**

The graph differentiates the umbrella ER package, EMR, ESD, pathology, staging, surgery, and surveillance ownership.

## Boundary → Runtime

**PASS.**

The boundary is explicit enough to prevent retrieval of PP-0194 as a substitute for detailed ESD, pathology, surgery, or individualized treatment content.

# Detailed Source-Traceability Table

| Source | Pages / Section | Claims Supported | Result |
|---|---|---|---|
| NCCN Gastric Cancer v2.2026 | GAST-A 1, p.18 | EMR/ESD role; larger specimen; depth; LVI; staging relevance | PASS |
| NCCN Gastric Cancer v2.2026 | GAST-A 2, p.19 | ER pathway; curative features | PASS |
| NCCN Gastric Cancer v2.2026 | GAST-A 3, p.20 | EMR/ESD treatment; ESD preference; expanded ESD; incomplete resection | PASS |
| NCCN Gastric Cancer v2.2026 | GAST-B, p.22 | EMR pathology reporting | PASS |
| NCI Gastric Cancer Treatment PDQ | p.17 | Classic EMR population; prospective evidence; recurrence | PASS |
| NCI Gastric Cancer Treatment PDQ | p.18 | Selected stage IA EMR | PASS |
| NCI Gastric Cancer Treatment PDQ | p.19 | Additional EMR evidence | PASS |
| NCI Treatment of Stomach Cancer | p.1 | Patient-facing EMR definition | PASS |
| Vietnamese Gastric Cancer Guideline | p.13 | Early gastric cancer endoscopic treatment context | PASS |
| Vietnamese Gastric Cancer Guideline | p.14 | EMR/ESD indications; en-bloc; curative assessment | PASS |
| ESMO-ASCO Global Curriculum 2023 | Gastric cancer curriculum | Multidisciplinary/endoscopic treatment context | PASS |

# Detailed Boundary Ownership Matrix

| Topic | PP-0194 Owns? | Reason |
|---|---|---|
| What is EMR? | YES | Atomic core concept. |
| Why EMR may treat selected early gastric cancer | YES | Core clinical role. |
| General ER strategy | NO | Umbrella package owns it. |
| EMR selection principles | YES | Modality-specific ownership. |
| ESD selection principles | NO | Dedicated ESD ownership. |
| EMR versus ESD strategic comparison | YES | Needed to understand modality choice. |
| Detailed ESD technique | NO | Dedicated ESD ownership. |
| Biopsy strategy | NO | Upstream biopsy package. |
| EMR specimen significance | YES | Core downstream interface. |
| Detailed pathology taxonomy | NO | Pathology package. |
| EMR pathology elements | YES | Necessary to explain curative assessment. |
| Detailed pathology methodology | NO | Pathology package. |
| EUS role before ER | SUPPORTING | Needed as an interface. |
| EUS technical methodology | NO | Dedicated staging package. |
| Gastrectomy as an alternative | SUPPORTING | Needed for downstream context. |
| Gastrectomy technique | NO | Surgical packages. |
| Lymphadenectomy rationale | SUPPORTING | Needed to explain nodal-risk logic. |
| Lymphadenectomy technique | NO | Surgical packages. |
| Systemic treatment after non-curative ER | SUPPORTING | Only transition is explained. |
| Systemic treatment algorithm | NO | Treatment packages. |
| Surveillance rationale | SUPPORTING | Needed after definitive EMR. |
| Detailed surveillance schedule | NO | Surveillance package/current guideline application. |
| Individualized treatment | NO | Outside educational ownership. |
| Individualized prognosis | NO | Outside educational ownership. |

# Detailed Evidence-Gap Disposition

| Gap | Disposition | Result |
|---|---|---|
| EMR technical steps | Explicitly excluded | PASS |
| Device settings | Explicitly excluded | PASS |
| EMR-specific universal complication rate | Not supplied | PASS — not invented |
| Anesthesia protocol | Explicitly excluded | PASS |
| Individual pathology interpretation | Explicitly excluded | PASS |
| Universal surveillance interval | Not asserted | PASS |
| Individual eligibility | Not asserted | PASS |
| Individual prognosis | Not asserted | PASS |
| Generalizability to low-incidence settings | Qualified | PASS |

# Detailed Version-Control QA

| Item | Result | Verification |
|---|---|---|
| Semantic version present | PASS | 1.0.0. |
| Date present | PASS | 2026-08-09. |
| Initial Gold release identified | PASS | Revision history present. |
| Locked decision identified | PASS | Decision status is APPROVED / LOCKED. |
| Governance version identified | PASS | CORE_WORKING_RULES v1.7. |
| Gold specification identified | PASS | FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1. |
| Source basis identified | PASS | Project Source Files. |

# Detailed Patient-Safety QA

## Safety Check 1 — Eligibility

**PASS.**

The package explains eligibility factors but does not instruct the patient to self-classify as an EMR candidate.

## Safety Check 2 — Cure

**PASS.**

The package repeatedly distinguishes technical removal from curative oncologic assessment.

## Safety Check 3 — Pathology

**PASS.**

The package explains the purpose of pathology without replacing expert pathology review.

## Safety Check 4 — Additional treatment

**PASS.**

The package explains that non-curative features may lead to further treatment without prescribing a specific individual pathway.

## Safety Check 5 — ESD

**PASS.**

The package does not encourage a patient to choose EMR or ESD independently.

## Safety Check 6 — Surgery

**PASS.**

The package explains why surgery may remain necessary without giving a surgical prescription.

## Safety Check 7 — Follow-up

**PASS.**

The package explains the need for surveillance without asserting a universal interval.

## Safety Check 8 — Evidence uncertainty

**PASS.**

Historical outcome data are clearly identified as cohort-level evidence.

# Final Integration Checklist

| Integration Requirement | Result |
|---|---|
| PP identity consistent | PASS |
| Title consistent | PASS |
| Four artifact names consistent | PASS |
| Version consistent | PASS |
| Scope consistent | PASS |
| Boundary consistent | PASS |
| Evidence sources consistent | PASS |
| Knowledge Graph consistent | PASS |
| Patient-facing style consistent | PASS |
| QA status consistent | PASS |
| No unsupported external evidence | PASS |
| No unresolved clinical blocker | PASS |
| Ready for repository integration | PASS |

# Final Reviewer Conclusion

The four-artifact package is internally coherent and source-grounded. The package is sufficiently deep for Gold production and intentionally preserves the modality-specific ownership of EMR without absorbing the umbrella ER strategy, ESD, detailed pathology, staging methodology, surgical technique, systemic treatment, or surveillance methodology.

The evidence is strongest for selected early gastric cancer, patient/lesion selection, curative-pathology concepts, and historical outcomes. The evidence is intentionally not stretched into a technical EMR manual or an individualized eligibility tool.

This is consistent with the Source-First Rule and the Absolute Gold Depth Rule.

# Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
